What Should Clinical Research Programs Include in Clinical Trial Budget Negotiations?
Clinical trial budget negotiations are more than a pricing exercise. For research programs, they help determine whether the full cost of study initiation, execution, oversight, and maintenance is identified and appropriately reflected in sponsor budgets. Commonly overlooked areas include data entry, study coordinator effort, outpatient clinic space and facility charges, principal investigator oversight, and administrative review effort.
Budget Negotiations in Industry-Sponsored Research
Clinical trial budget negotiations are a critical, yet often overlooked, control point in the industry-sponsored research lifecycle. While academic medical centers, hospitals, physician practices, and other organizations with clinical research programs frequently focus on study start-up timelines and overall financial sustainability, the details embedded within negotiated budgets directly affect operational execution, billing compliance, and the financial health of both the research program and the broader healthcare organization.
Inadequate budgeting for research infrastructure, including personnel, systems, and oversight, can leave programs unable to sustain operations without supplemental funding, ultimately threatening long-term viability. Even mature research programs often leave significant value on the table by failing to adequately account for certain costs or by absorbing them into overhead rather than study budgets.
At the same time, regulators and enforcement agencies continue to emphasize that clinical trial financial arrangements must be fair, transparent, and supported by documented effort. Enforcement activity from the U.S. Department of Justice and Department of Health and Human Services Office of Inspector General has highlighted risks associated with improper allocation of research costs and cost shifting between sponsors and federal healthcare programs, and fraud and abuse laws and fair market value requirements reinforce the need for appropriate compensation structures.
As a result, clinical trial budgets should be viewed not simply as financial tools requiring keen negotiation but also as key compliance controls and long-term operational drivers.
Although many of the operational, financial, and compliance considerations discussed in this article apply across the research enterprise, this discussion focuses primarily on commercially sponsored clinical trials, where budget negotiation represents a formal component of study start-up. Government-funded and other sponsored research activities often involve similar resource allocation, effort documentation, and compliance considerations but may follow different funding, award, and budget development processes.
Five Overlooked Opportunities in Clinical Trial Budgets
Outlined below are five commonly overlooked categories in the budget-negotiation process that can significantly impact the financial sustainability of clinical research programs:
- Data entry and system documentation
- Study coordinator effort
- Outpatient clinic space and facility charges
- Principal investigator (PI) oversight
- Budget negotiation and administrative review effort
Organizations that more deliberately address these areas during budget negotiations are often better positioned to recover costs, support research infrastructure, reduce compliance risk, and achieve a financially sustainable program.
1. Data Entry and System Documentation
Why this Matters
Data entry is a critical and often resource-intensive component of clinical trial execution, requiring ongoing effort to capture, verify, reconcile, and report study data across multiple systems throughout the study lifecycle. Because these activities are essential to data integrity, regulatory compliance, and sponsor reporting, organizations should ensure the associated staffing and resource needs are adequately accounted for in trial budgets.
Where Breakdowns Occur
Data entry is often folded into general study coordinator effort rather than evaluated as a distinct staffing resource need. This assumption, however, can result in budgets that underestimate the true level of effort required, particularly for complex protocols with high data volume, frequent queries, or intensive monitoring requirements.
How to Address It
Sufficiently account for data entry by first reviewing the protocol-defined data requirements in conjunction with the study-specific electronic case report forms (eCRF) to understand the volume and complexity of data points that will need to be captured. This level of review provides a more accurate foundation for estimating the true effort associated with data entry activities.
Depending on sponsor structure and preferences, this effort may be captured as a discrete line item (e.g., hourly data entry support) or incorporated into overall study coordinator time. Regardless of the approach, the critical objective is to ensure that data entry effort is explicitly evaluated and reflected in the budget, rather than assumed to be covered within standard per-visit coordinator allocations.
2. Study Coordinator Effort
Why this Matters
Study coordinators represent one of the most significant operational resources in clinical research, serving as the primary drivers of patient recruitment, visit management, protocol compliance, documentation, regulatory coordination, and day-to-day study execution. Given the breadth and variability of these responsibilities across studies and within organizations, accurately accounting for coordinator effort in trial budgets is essential to sustaining study performance, supporting successful recruitment, and ensuring adequate operational resources throughout the study lifecycle.
Where Breakdowns Occur
Coordinator fees are often underestimated because budgeting models focus primarily on time spent during patient visits and fail to account for the full scope of coordinator responsibilities. Beyond direct patient interactions, coordinators manage patient communications, scheduling, ancillary testing, study coordination, monitoring visits, and ongoing collaboration with clinical and research staff, all of which require significant effort that should be reflected in study budgets, particularly for complex protocols and high-enrollment studies.
How to Address It
Account for coordinator activities by first evaluating the full scope of study coordinator responsibilities beyond scheduled patient visits, including patient communication and follow-up, visit preparation, coordination of ancillary testing, cross-departmental navigation, support during monitoring visits (including time spent preparing for and responding to monitor inquiries), and support for clinical and research staff. This broader view provides a more accurate foundation for estimating the total effort required to support study execution.
Coordinator effort may be structured in different ways depending on sponsor preferences, including incorporation into per-visit fees or allocation through hourly rates. Because most clinical trials are structured on a per-visit basis, organizations often apply a coordinator hourly rate to estimate per-visit effort (i.e., calculating time required for visit preparation, patient interaction, and post-visit documentation).
Organizations, however, should also proactively account for coordinator time associated with items such as routine monitoring visits, which occur periodically throughout the study and require significant staff involvement over one or multiple days, and any other responsibility the coordinator is performing. Such effort is frequently overlooked and should be reflected through a defined per-monitoring-visit fee or similar budget mechanism. Regardless of structure, the critical objective is to ensure that the full scope of coordinator activities is explicitly considered and reflected in the budget.
3. Outpatient Clinic Space and Facility Charges
Why this Matters
Clinical trials often rely on outpatient clinic space, exam rooms, and support services that carry real operational costs, yet these resources are frequently not captured or adequately reimbursed within study budgets. When clinical space is used to support research activities, organizations should ensure those costs are appropriately reflected in sponsor budgets to support cost recovery, preserve financial sustainability, and avoid potential regulatory concerns associated with providing free or below-market resources to sponsors.
Appropriate valuation and recovery of facility-related costs also support compliance with research billing, fair market value requirements, and financial integrity expectations by helping ensure that research activities are appropriately accounted for and supported by documented resource utilization. Failure to account for and recover these costs can reduce visibility into the true cost of research operations, result in lost revenue opportunities, and create potential compliance concerns.
Where Breakdowns Occur
Facility charges for clinic space and related support services are often omitted or inconsistently applied, particularly when standard outpatient space is used for research visits without generating a corresponding charge. This oversight results in clinic utilization being absorbed operationally rather than recognized as a billable resource.
How to Address It
Establish clear methodologies for capturing and applying facility-related charges when outpatient clinic space is used to support research activities. This step includes aligning research-related facility charges with existing clinic billing practices, such as applying charges consistent with those associated with applicable CPT[1]-coded services or standard visit-based resource utilization.
Whether incorporated as a discrete facility fee or embedded within visit-level charges, the key is ensuring that clinic space and associated support services are consistently accounted for in a manner that reflects how those resources are used in routine patient care. Consistent application of this approach improves transparency, supports defensibility during sponsor negotiations, and helps ensure appropriate and compliant recovery of facility-related costs associated with clinical research.
4. Principal Investigator (PI) Oversight
Why this Matters
PI oversight is a regulatory requirement and a core component of study integrity. Responsibilities include patient safety oversight, protocol compliance, and review of study data. This role requires specialized clinical expertise, and compensation should reflect the level of responsibility and involvement across PI roles while remaining defensible from a regulatory perspective. Because PI effort is often negotiated as part of the clinical trial budget, accurately identifying and quantifying investigator responsibilities are critical to ensuring budgets appropriately capture the time, expertise, and oversight required to conduct the study.
Where Breakdowns Occur
PI oversight is commonly budgeted through a flat fee, but unless that fee is developed using a comprehensive assessment of investigator responsibilities, it may significantly understate the true level of effort required. In addition to study oversight, PIs often perform protocol-specific assessments, start-up activities, regulatory and safety oversight, staff supervision, data review, and other administrative functions throughout the study lifecycle. It is important that budgets accurately reflect both direct and indirect investigator time to support fair compensation, compliance, and sustained physician engagement.
How to Address It
Structure PI budgeted reimbursement to reflect ongoing oversight responsibilities and discrete clinical activities performed as part of study visits. A flat per-visit PI oversight fee can serve as a baseline for general supervisory responsibilities, and procedure-level activities should be separately identified and incorporated into visit-level budgets as applicable. These activities should be mapped upon receipt of the budget from the sponsor and collectively considered when evaluating compensation.
Additionally, ensure that PI compensation is consistent with fair market value (FMV) and reflective of the effort and expertise required. Industry benchmark surveys and other objective market data can be used to validate that reimbursement for identified PI activities is reasonable and appropriately reflects the anticipated time commitment and complexity of the study. This approach helps align reimbursement more closely with actual services performed.
5. Budget Negotiation and Administrative Review Effort
Why this Matters
Clinical trial budget development and negotiation require coordinated input from research administration, finance, compliance, principal investigators, and study coordinators to ensure budgets accurately reflect protocol complexity, sponsor requirements, and operational realities. Organizations incur significant administrative effort throughout the study lifecycle beyond initial contract negotiations. These efforts can include clinical trial management system (CTMS) maintenance, calendar builds, institutional review board (IRB) submissions, coverage analyses, and other start-up and study management activities that should be appropriately recognized and reimbursed within trial budgets.
Where Breakdowns Occur
Administrative and budget negotiation effort is often underestimated when operational input is not fully incorporated into the budgeting process. Activities such as CTMS configuration, calendar builds, IRB submissions, coverage analyses, screening failures, unscheduled visits, and protocol amendments require substantial administrative resources throughout the study lifecycle and should be appropriately accounted for to avoid unbudgeted effort and support effective study execution.
How to Address It
Take a lifecycle-based approach to budgeting for negotiation and administrative effort, ensuring that both start-up and ongoing maintenance activities are appropriately captured. This approach begins with incorporating cross-functional input from the study team, including the PI and coordinators, to identify protocol-specific requirements and administrative activities that may not be evident from the protocol alone.
While many organizations include distinct administrative or negotiation fees at start-up, equal consideration should be given to ongoing maintenance activities throughout the trial. These activities should be captured on a per-event or per-activity basis rather than subject to fixed caps, particularly for items such as amendments, screening activities for participants who are ultimately found ineligible for enrollment, and unscheduled visits that introduce incremental administrative effort.
Key Takeaways
Clinical trial budget negotiations are a critical component of research compliance, operational success, and long-term sustainability. Academic medical centers, hospitals, physician practices, and other organizations with clinical research programs that accurately account for the full cost of study start-up, execution, oversight, and ongoing maintenance activities and actively monitor financial performance throughout the study lifecycle are better positioned to support compliant billing practices, avoid under-budgeted studies, and maintain financially sustainable research programs.
As research complexity continues to increase, effective budget negotiation is no longer optional; it is essential to ensuring the long-term success and integrity of clinical research operations.
PYA Can Help
For more than 40 years, PYA has helped our healthcare clients negotiate clinical trial budgets that support compliant and financially sustainable research programs.
Learn more!
Read PYA’s related article, Research Compliance in Today’s Healthcare Environment: Five Compliance Challenges and How to Address Them.
Download PYA’s helpful resource: Building and Sustaining Research Compliance Programs.
Learn about PYA’s Clinical Research Administration Office and our Healthcare Advisory Services.
[1] Current Procedural Terminology (CPT) is a registered trademark of the American Medical Association.
